nach oben

The International Journal of Cardiovascular Imaging

Erschienen in:

04.02.2019 | Original Paper

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension

verfasst von: Takumi Toya, Yuji Nagatomo, Kazuki Kagami, Midori Yukino, Risako Yasuda, Takayuki Namba, Yasuo Ido, Shinichi Kobayashi, Nobuyuki Masaki, Hirotaka Yada, Fumihiko Kimura, Takeshi Adachi

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Periodic echo-based screening to detect early stages of a rare complication of dasatinib, pulmonary arterial hypertension (PAH), is inefficient and weakens the potential benefit of dasatinib as a potent drug for chronic myelogenous leukemia (CML). This study aimed to identify the predisposing factors of DASA-PAH to stratify high-risk patients for dasatinib-induced PAH (DASA-PAH).

Methods

Sixty consecutive adult patients who received dasatinib were enrolled in this case-control study. We defined DASA-PAH when at least one of the following four criteria was met: (1) recent electrocardiographic changes indicating right ventricular pressure overload, (2) estimated systolic pulmonary arterial pressure > 40 mmHg measured by Doppler echocardiography; (3) computed tomography (CT)-measured pulmonary artery to aorta diameter (PaD/AoD) ratio > 1; and (4) mean pulmonary arterial pressure > 25 mmHg and pulmonary artery wedge pressure < 15 mmHg measured by right heart catheterization.

Results

We identified 13 patients with DASA-PAH among 59 patients analyzed. Baseline PaD/AoD ratios of patients who developed DASA-PAH (PH group) were significantly larger than those who did not (NPH group). A dramatic rise in PaD/AoD ratio after dasatinib treatment was observed. Interestingly, the EUTOS score and spleen size were significantly smaller in the PH than in the NPH group.

Conclusion

High baseline PaD/AoD ratio and low EUTOS score were associated with DASA-PAH development. The spleen might play a protective role against DASA-PAH.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401. https://doi.org/10.1126/science.1099480 CrossRefPubMed

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494–500. https://doi.org/10.1182/blood-2013-06-511592 CrossRefPubMedPubMedCentral

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333–2340. https://doi.org/10.1200/jco.2015.64.8899 CrossRefPubMedPubMedCentral

Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914. https://doi.org/10.1200/jco.2007.12.0329 CrossRefPubMed

Moslehi JJ, Deininger M (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33(35):4210–4218. https://doi.org/10.1200/jco.2015.62.4718 CrossRefPubMedPubMedCentral

Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561. https://doi.org/10.1093/jnci/djr060 CrossRefPubMed

Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D (2017) Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 50(1). https://doi.org/10.1183/13993003.00217-2017

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90(11):1060–1064. https://doi.org/10.1002/ajh.24174 CrossRefPubMed

Baumgart B, Guha M, Hennan J, Li J, Woicke J, Simic D, Graziano M, Wallis N, Sanderson T, Bunch RT (2017) In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. Cancer Chemother Pharmacol 79(4):711–723. https://doi.org/10.1007/s00280-017-3264-2 CrossRefPubMed

10.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Maneglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M (2016) Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Investig 126(9):3207–3218. https://doi.org/10.1172/jci86249 CrossRefPubMedPubMedCentral

11.

Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801. https://doi.org/10.1093/eurheartj/ehw211 CrossRefPubMed

12.

McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):14s–34s. https://doi.org/10.1378/chest.126.1_suppl.14S CrossRefPubMed

13.

Al-Naamani K, Hijal T, Nguyen V, Andrew S, Nguyen T, Huynh T (2008) Predictive values of the electrocardiogram in diagnosing pulmonary hypertension. Int J Cardiol 127(2):214–218. https://doi.org/10.1016/j.ijcard.2007.06.005 CrossRefPubMed

14.

Nikus K, Perez-Riera AR, Konttila K, Barbosa-Barros R (2018) Electrocardiographic recognition of right ventricular hypertrophy. J Electrocardiol 51(1):46–49. https://doi.org/10.1016/j.jelectrocard.2017.09.004 CrossRefPubMed

15.

Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE, Olson JJ, Troughton RW (2015) Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 28(1):40–56. https://doi.org/10.1016/j.echo.2014.09.009 CrossRefPubMed

16.

McQuillan BM, Picard MH, Leavitt M, Weyman AE (2001) Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104(23):2797–2802CrossRefPubMed

17.

Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT (2014) CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 145(4):824–832. https://doi.org/10.1378/chest.13-1422 CrossRefPubMed

18.

Ng CS, Wells AU, Padley SP (1999) A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 14(4):270–278CrossRefPubMed

19.

Corson N, Armato SG 3rd, Labby ZE, Straus C, Starkey A, Gomberg-Maitland M (2014) CT-based pulmonary artery measurements for the assessment of pulmonary hypertension. Acad Radiol 21(4):523–530. https://doi.org/10.1016/j.acra.2013.12.015 CrossRefPubMedPubMedCentral

20.

Rajaram S, Swift AJ, Condliffe R, Johns C, Elliot CA, Hill C, Davies C, Hurdman J, Sabroe I, Wild JM, Kiely DG (2015) CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax 70(4):382–387. https://doi.org/10.1136/thoraxjnl-2014-206088 CrossRefPubMed

21.

Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O’Callaghan DS, Jais X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17):2128–2137. https://doi.org/10.1161/circulationaha.111.079921 CrossRefPubMed

22.

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317 CrossRefPubMed

23.

Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V (2017) A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulm Circ 7(4):808–812. https://doi.org/10.1177/2045893217733444 CrossRefPubMedPubMedCentral

24.

Quilot FM, Georges M, Favrolt N, Beltramo G, Foignot C, Grandvuillemin A, Montani D, Bonniaud P, Camus P (2016) Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 47(2):676–679. https://doi.org/10.1183/13993003.01110-2015 CrossRefPubMed

25.

Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, Grimminger F, Grunig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127(10):1128–1138. https://doi.org/10.1161/circulationaha.112.000765 CrossRefPubMed

26.

Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ (2014) Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE 9(3):e92146. https://doi.org/10.1371/journal.pone.0092146 CrossRefPubMedPubMedCentral

27.

Jardim C, Rochitte CE, Humbert M, Rubenfeld G, Jasinowodolinski D, Carvalho CR, Souza R (2007) Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. Eur Respir J 29(3):476–481. https://doi.org/10.1183/09031936.00016806 CrossRefPubMed

28.

Estepar RS, Kinney GL, Black-Shinn JL, Bowler RP, Kindlmann GL, Ross JC, Kikinis R, Han MK, Come CE, Diaz AA, Cho MH, Hersh CP, Schroeder JD, Reilly JJ, Lynch DA, Crapo JD, Wells JM, Dransfield MT, Hokanson JE, Washko GR (2013) Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med 188(2):231–239. https://doi.org/10.1164/rccm.201301-0162OC CrossRefPubMedPubMedCentral

29.

Naeije R, Barbera JA (2001) Pulmonary hypertension associated with COPD. Crit Care 5(6):286–289CrossRefPubMedPubMedCentral

30.

Crary SE, Buchanan GR (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114(14):2861–2868. https://doi.org/10.1182/blood-2009-04-210112 CrossRefPubMedPubMedCentral

31.

Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H (2006) Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 81(9):670–675. https://doi.org/10.1002/ajh.20640 CrossRefPubMed

32.

Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350(9):886–895. https://doi.org/10.1056/NEJMoa035477 CrossRefPubMed

33.

Cederleuf H, Bjerregard Pedersen M, Jerkeman M, Relander T, d’Amore F, Ellin F (2017) The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Haematol 178(5):739–746. https://doi.org/10.1111/bjh.14740 CrossRefPubMed

34.

Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A (2008) Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 93(6):941–942. https://doi.org/10.3324/haematol.12460 CrossRefPubMed

35.

Jais X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A, Fadel E, Dartevelle P, Simonneau G, Humbert M (2005) Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 60(12):1031–1034. https://doi.org/10.1136/thx.2004.038083 CrossRefPubMedPubMedCentral

36.

Hoeper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H (1999) Pulmonary hypertension after splenectomy? Ann Intern Med 130(6):506–509CrossRefPubMed

Titel: Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension
verfasst von: Takumi Toya
Yuji Nagatomo
Kazuki Kagami
Midori Yukino
Risako Yasuda
Takayuki Namba
Yasuo Ido
Shinichi Kobayashi
Nobuyuki Masaki
Hirotaka Yada
Fumihiko Kimura
Takeshi Adachi
Publikationsdatum: 04.02.2019
Verlag: Springer Netherlands
Erschienen in: The International Journal of Cardiovascular Imaging / Ausgabe 8/2019
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-019-01548-2

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

3D-assessment of RVOT dimensions prior percutaneous pulmonary valve implantation: comparison of contrast-enhanced magnetic resonance angiography versus 3D steady-state free precession sequence

Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure

Pulmonary arteriovenous malformations

Imaging and Surgical Treatment of Primary Pulmonary Artery Sarcoma

Advanced imaging in pulmonary hypertension: emerging techniques and applications

State of the art: utility of multi-energy CT in the evaluation of pulmonary vasculature

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie